SG11202106637SA - Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer - Google Patents
Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancerInfo
- Publication number
- SG11202106637SA SG11202106637SA SG11202106637SA SG11202106637SA SG11202106637SA SG 11202106637S A SG11202106637S A SG 11202106637SA SG 11202106637S A SG11202106637S A SG 11202106637SA SG 11202106637S A SG11202106637S A SG 11202106637SA SG 11202106637S A SG11202106637S A SG 11202106637SA
- Authority
- SG
- Singapore
- Prior art keywords
- mat2a
- aza
- methods
- treating cancer
- heterobicyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862785519P | 2018-12-27 | 2018-12-27 | |
| PCT/US2019/068652 WO2020139991A1 (en) | 2018-12-27 | 2019-12-27 | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202106637SA true SG11202106637SA (en) | 2021-07-29 |
Family
ID=69400625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202106637SA SG11202106637SA (en) | 2018-12-27 | 2019-12-27 | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US12077534B2 (hu) |
| EP (1) | EP3902803B1 (hu) |
| JP (2) | JP7418441B2 (hu) |
| KR (1) | KR20220051301A (hu) |
| CN (1) | CN113454085B (hu) |
| AR (1) | AR117544A1 (hu) |
| AU (1) | AU2019416349B2 (hu) |
| BR (1) | BR112021012595A2 (hu) |
| CA (1) | CA3124952A1 (hu) |
| CL (1) | CL2021001721A1 (hu) |
| CO (1) | CO2021009879A2 (hu) |
| CR (1) | CR20210410A (hu) |
| DK (1) | DK3902803T3 (hu) |
| EA (1) | EA202191801A1 (hu) |
| ES (1) | ES2942310T3 (hu) |
| FI (1) | FI3902803T3 (hu) |
| GE (1) | GEP20237519B (hu) |
| HR (1) | HRP20230161T1 (hu) |
| HU (1) | HUE061834T2 (hu) |
| IL (1) | IL284326B2 (hu) |
| JO (1) | JOP20210172A1 (hu) |
| LT (1) | LT3902803T (hu) |
| MA (1) | MA54608B1 (hu) |
| MD (1) | MD3902803T2 (hu) |
| MX (1) | MX2021007829A (hu) |
| PE (1) | PE20212090A1 (hu) |
| PL (1) | PL3902803T3 (hu) |
| PT (1) | PT3902803T (hu) |
| RS (1) | RS64135B1 (hu) |
| SA (1) | SA521422405B1 (hu) |
| SG (1) | SG11202106637SA (hu) |
| SI (1) | SI3902803T1 (hu) |
| TW (1) | TWI816962B (hu) |
| UA (1) | UA127525C2 (hu) |
| WO (1) | WO2020139991A1 (hu) |
| ZA (1) | ZA202104423B (hu) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11077101B1 (en) | 2018-07-18 | 2021-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
| CN113166078A (zh) | 2018-12-10 | 2021-07-23 | 伊迪亚生物科学有限公司 | 2-氧代喹唑啉衍生物作为甲硫氨酸腺苷转移酶2a抑制剂 |
| JP2023536589A (ja) * | 2020-07-31 | 2023-08-28 | タンゴ セラピューティクス， インコーポレイテッド | Ｍｔａｐ欠損及び／またはｍｔａ蓄積癌の治療に有用なピペリジン－１－イル－ｎ－ピリジン－３－イル－２－オキソアセトアミド誘導体 |
| WO2022052924A1 (zh) * | 2020-09-11 | 2022-03-17 | 上海凌达生物医药有限公司 | 一类含氮稠环类化合物的制备方法和用途 |
| CN115141202A (zh) * | 2021-03-29 | 2022-10-04 | 武汉人福创新药物研发中心有限公司 | 嘧啶并吡嗪酮化合物及其用途 |
| CN117412967A (zh) * | 2021-06-02 | 2024-01-16 | 南京正大天晴制药有限公司 | 蛋氨酸腺苷转移酶2a抑制剂 |
| AR127404A1 (es) | 2021-10-20 | 2024-01-17 | Insilico Medicine Ip Ltd | Inhibidores de la metionina adenosiltransferasa 2a (mat2a) y usos de los mismos |
| EP4448517A1 (en) * | 2021-12-17 | 2024-10-23 | Tango Therapeutics, Inc. | Crystalline form of n-(6-amino-5-methylpyridin-3-yl)-2-(benzo[d]thiazol-5-yl)-5-methylpiperidin-1-yl)-2-oxoacetamide, pharmaceutical compositions and methods of use thereof |
| WO2023116696A1 (zh) * | 2021-12-21 | 2023-06-29 | 南京正大天晴制药有限公司 | 蛋氨酸腺苷转移酶2a的杂环抑制剂 |
| CN118742550A (zh) * | 2022-03-11 | 2024-10-01 | 赛诺哈勃药业（成都）有限公司 | 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用 |
| WO2024080788A1 (ko) | 2022-10-13 | 2024-04-18 | 한미약품 주식회사 | 신규한 트리사이클 유도체 화합물 및 이의 용도 |
| WO2024183778A1 (zh) * | 2023-03-06 | 2024-09-12 | 甘李药业股份有限公司 | 一种甲硫氨酸腺苷转移酶2a抑制剂及其医药用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6576420B1 (en) | 1998-06-23 | 2003-06-10 | Regents Of The University Of California | Method for early diagnosis of, and determination of prognosis in, cancer |
| KR100571339B1 (ko) | 2000-08-31 | 2006-04-17 | 에프. 호프만-라 로슈 아게 | 세포증식 억제제로서의 7-옥소 피리도피리미딘 |
| EP1317448B2 (en) | 2000-09-15 | 2011-05-04 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US7098332B2 (en) | 2002-12-20 | 2006-08-29 | Hoffmann-La Roche Inc. | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones |
| US8664276B2 (en) | 2011-01-28 | 2014-03-04 | University Of Kentucky Research Foundation | Stilbene analogs and methods of treating cancer |
| WO2016064960A1 (en) | 2014-10-22 | 2016-04-28 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| IL265115B (en) * | 2016-08-31 | 2022-07-01 | Agios Pharmaceuticals Inc | Inhibitors of metabolic processes in the cell |
| US11053196B2 (en) | 2017-05-22 | 2021-07-06 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| MA52232A (fr) * | 2018-03-30 | 2021-02-17 | Agios Pharmaceuticals Inc | Inhibiteurs hétérobicycliques de mat2a et leurs méthodes d'utilisation pour le traitement du cancer |
| EP3902804A1 (en) * | 2018-12-27 | 2021-11-03 | Les Laboratoires Servier SAS | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer |
| AR119046A1 (es) * | 2019-05-31 | 2021-11-17 | Agios Pharmaceuticals Inc | Inhibidores heterobicíclicos de mat2a y su uso para el tratamiento de diversos tipos de cáncer |
-
2019
- 2019-12-27 JO JOP/2021/0172A patent/JOP20210172A1/ar unknown
- 2019-12-27 EA EA202191801A patent/EA202191801A1/ru unknown
- 2019-12-27 PL PL19845796.2T patent/PL3902803T3/pl unknown
- 2019-12-27 US US17/418,442 patent/US12077534B2/en active Active
- 2019-12-27 PT PT198457962T patent/PT3902803T/pt unknown
- 2019-12-27 MD MDE20211082T patent/MD3902803T2/ro unknown
- 2019-12-27 DK DK19845796.2T patent/DK3902803T3/da active
- 2019-12-27 MA MA54608A patent/MA54608B1/fr unknown
- 2019-12-27 JP JP2021538127A patent/JP7418441B2/ja active Active
- 2019-12-27 AU AU2019416349A patent/AU2019416349B2/en active Active
- 2019-12-27 PE PE2021001086A patent/PE20212090A1/es unknown
- 2019-12-27 CA CA3124952A patent/CA3124952A1/en active Pending
- 2019-12-27 BR BR112021012595-7A patent/BR112021012595A2/pt active Search and Examination
- 2019-12-27 TW TW108148216A patent/TWI816962B/zh active
- 2019-12-27 MX MX2021007829A patent/MX2021007829A/es unknown
- 2019-12-27 CN CN201980092742.2A patent/CN113454085B/zh active Active
- 2019-12-27 LT LTEPPCT/US2019/068652T patent/LT3902803T/lt unknown
- 2019-12-27 FI FIEP19845796.2T patent/FI3902803T3/fi active
- 2019-12-27 RS RS20230240A patent/RS64135B1/sr unknown
- 2019-12-27 ES ES19845796T patent/ES2942310T3/es active Active
- 2019-12-27 IL IL284326A patent/IL284326B2/en unknown
- 2019-12-27 SI SI201930515T patent/SI3902803T1/sl unknown
- 2019-12-27 HR HRP20230161TT patent/HRP20230161T1/hr unknown
- 2019-12-27 CR CR20210410A patent/CR20210410A/es unknown
- 2019-12-27 WO PCT/US2019/068652 patent/WO2020139991A1/en active Application Filing
- 2019-12-27 GE GEAP201915703A patent/GEP20237519B/en unknown
- 2019-12-27 HU HUE19845796A patent/HUE061834T2/hu unknown
- 2019-12-27 KR KR1020217023828A patent/KR20220051301A/ko unknown
- 2019-12-27 AR ARP190103903A patent/AR117544A1/es unknown
- 2019-12-27 EP EP19845796.2A patent/EP3902803B1/en active Active
- 2019-12-27 UA UAA202104321A patent/UA127525C2/uk unknown
- 2019-12-27 SG SG11202106637SA patent/SG11202106637SA/en unknown
-
2021
- 2021-06-25 CL CL2021001721A patent/CL2021001721A1/es unknown
- 2021-06-25 ZA ZA2021/04423A patent/ZA202104423B/en unknown
- 2021-06-27 SA SA521422405A patent/SA521422405B1/ar unknown
- 2021-07-27 CO CONC2021/0009879A patent/CO2021009879A2/es unknown
-
2023
- 2023-12-11 JP JP2023208546A patent/JP2024015340A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277665A (en) | Heterocyclic inhibitors of MAT2A and methods of use for cancer therapy | |
| IL284324A (en) | Aza-heterobicyclic MAT2A inhibitors and methods for use in the treatment of cancer | |
| IL284326A (en) | Aza-heterobicyclic MAT2A inhibitors and methods for use in the treatment of cancer | |
| IL288395A (en) | Mat2a tricyclic inhibitors and methods for use in cancer therapy | |
| IL272948B1 (en) | enpp1 inhibitors and their use for cancer treatment | |
| IL272877A (en) | SHP2 inhibitory compositions and methods for cancer treatment | |
| EP3464643A4 (en) | USE OF EZH2 INHIBITORS FOR THE TREATMENT OF CANCER | |
| IL268814A (en) | Preparations and methods for the treatment of cancer | |
| IL274198A (en) | Use of Nox inhibitors to treat cancer | |
| IL277918A (en) | A combination of LIF inhibitors and PD-1 AXIS inhibitors for use in cancer therapy | |
| HK1244436A1 (zh) | 治療癌症的hsp90抑制劑和pd-1抑制劑的組合療法 | |
| EP3576766A4 (en) | CYCLIN-G1 INHIBITORS AND RELATED METHODS FOR TREATING CANCER | |
| IL276203A (en) | Compounds and methods for treating cancer | |
| EP3630080A4 (en) | USE OF EZH2 INHIBITORS FOR THE TREATMENT OF CANCER | |
| IL291424A (en) | Use of dkk-1 inhibitors to treat cancer | |
| IL287538A (en) | Preparations and methods for the treatment of cancer | |
| PL3630112T3 (pl) | Kombinacja regorafenibu i niwolumabu w leczeniu nowotworu | |
| GB201709417D0 (en) | Cyclin dependent kinase 4/6 inhibitors for use in methods of treating cancer | |
| IL288003A (en) | Cancer treatment methods using chk1 inhibitors | |
| GB201709076D0 (en) | Parp inhibitors for use in methods of treating cancer | |
| IL263184A (en) | Method of treating cancer and compositions for same | |
| IL283912B (en) | Methods for treating cancer using the platenoside molecule and its isomers | |
| IL288591A (en) | Methods and uses for cancer treatment |